Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer

被引:97
作者
Burkhardt, M
Mayordomo, E
Winzer, KJ
Fritzsche, F
Gansukh, T
Pahl, S
Weichert, W
Denkert, C
Guski, H
Dietel, M
Kristiansen, G
机构
[1] Charite, Inst Pathol, Berlin, Germany
[2] Charite, Interdisciplinary Breast Ctr, Berlin, Germany
关键词
D O I
10.1136/jcp.2005.028209
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Activated leucocyte cell adhesion molecule (ALCAM, CD166) is a cell surface member of the immunoglobulin superfamily. ALCAM expression has prognostic relevance in prostate and colon cancer. Objective: To evaluate ALCAM protein expression in breast cancer by immunohistochemistry and to correlate expression levels with clinicopathological data. Methods: 162 primary breast carcinomas with a mean clinical follow up time of 53 months were immunostained using a monoclonal ALCAM antibody. The staining was evaluated as an immunoreactive score (IRS) and grouped into low v high for both membranous and cytoplasmic staining. Results: Intraductal and invasive carcinomas showed a higher ALCAM expression (median IRS 4 and 6 respectively) than normal breast tissue (IRS 2). In univariate survival analyses a significant association of high cytoplasmic ALCAM expression with shortened patient disease-free survival (mean (SD) five year non-progression rate, 69.4 (4.6)% v 49.4 (11.1)%, p=0.0142) was found. In multivariate analyses of disease-free survival times, high cytoplasmic ALCAM expression (relative risk (RR)=2.086, p=0.026) and nodal status (RR=2.246, p=0.035) were significantly associated with earlier disease progression, whereas tumour grading (RR=1.6, p=0.052) was of borderline significance. Conclusions: The data suggest that strong cytoplasmic ALCAM expression in primary breast cancer, as detected by immunohistochemistry, might be a new marker for a more aggressive breast cancer biology.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 35 条
[1]  
[Anonymous], 2003, UROONCOLOGY, DOI DOI 10.1080/15610950310001632322
[2]   Identification of differentially expressed genes in oral squamous cell carcinoma [J].
Arora, S ;
Matta, A ;
Shukla, NK ;
Deo, SVS ;
Ralhan, R .
MOLECULAR CARCINOGENESIS, 2005, 42 (02) :97-108
[3]   Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours [J].
Borlak, J ;
Meier, T ;
Halter, R ;
Spanel, R ;
Spanel-Borowski, K .
ONCOGENE, 2005, 24 (11) :1809-1819
[4]   The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry [J].
Bowen, MA ;
Bajorath, J ;
Siadak, AW ;
Modrell, B ;
Malacko, AR ;
Marquardt, H ;
Nadler, SG ;
Aruffo, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (29) :17390-17396
[5]   CLONING, MAPPING, AND CHARACTERIZATION OF ACTIVATED LEUKOCYTE-CELL ADHESION MOLECULE (ALCAM), A CD6 LIGAND [J].
BOWEN, MA ;
PATEL, DD ;
LI, X ;
MODRELL, B ;
MALACKO, AR ;
WANG, WC ;
MARQUARDT, H ;
NEUBAUER, M ;
PESANDO, JM ;
FRANCKE, U ;
HAYNES, BF ;
ARUFFO, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (06) :2213-2220
[6]  
Bowen MA, 2000, PROTEINS, V40, P420
[7]   Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin [J].
Choi, S ;
Kobayashi, M ;
Wang, JX ;
Habelhah, H ;
Okada, F ;
Hamada, J ;
Moriuchi, T ;
Totsuka, Y ;
Hosokawa, M .
CLINICAL & EXPERIMENTAL METASTASIS, 2000, 18 (01) :45-50
[8]  
Degen WGJ, 1998, AM J PATHOL, V152, P805
[9]  
Duffy MJ, 2002, CLIN CHEM, V48, P1194
[10]   Expression of luminal and basal cytokeratins in human breast carcinoma [J].
El-Rehim, DMA ;
Pinder, SE ;
Paish, CE ;
Bell, J ;
Blamey, R ;
Robertson, JFR ;
Nicholson, RI ;
Ellis, IO .
JOURNAL OF PATHOLOGY, 2004, 203 (02) :661-671